Goldman Sachs Group Inc Iovance Biotherapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,749,876 shares of IOVA stock, worth $11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,749,876
Previous 5,571,902
14.75%
Holding current value
$11 Million
Previous $18.6 Million
55.97%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding IOVA
# of Institutions
293Shares Held
234MCall Options Held
1.14MPut Options Held
1.15M-
Mhr Fund Management LLC New York, NY29MShares$67.2 Million8.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA25.1MShares$58.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$49.2 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR11.8MShares$27.4 Million0.94% of portfolio
-
State Street Corp Boston, MA9.89MShares$22.9 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $366M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...